Cargando…
EGFR突变晚期非小细胞肺癌患者后线接受免疫治疗的疗效分析
BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitor monotherapy is reported to have little effect in advanced non-small cell lung cancer (NSCLC) patients with driver oncogenes. However, recent studies have shown that some patients with driver genes are still benefit from combination immunotherapy...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174113/ https://www.ncbi.nlm.nih.gov/pubmed/34034457 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.104.06 |